A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)

NCT06242652 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Ankylosing Spondylitis

Interventions

DRUG: 608 Dose A
DRUG: 608 Dose B
DRUG: 608 Dose C
DRUG: Adalimumab
DRUG: Placebo

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.